AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) – Forecast and Market Analysis to 2022

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. AbbVie is developing an interferon-free HCV regimen that is a combination of the following three or four drugs: ABT-450 is an inhibitor of the HCV protease. This enzyme is required for viral polyprotein processing, which makes the protease essential for HCV replication (Asselah and Marcellin, 2013). Inhibitors of the HCV protease are, therefore, attractive antiviral drugs. ABT-450 is boosted with ritonavir. ABT-267 is an inhibitor of the HCV NS5A protein, which is unique to HCV. The protein is essential for multiple functions in the viral lifecycle, including HCV RNA replication, despite not having any enzymatic activity (Hunt and Pockros, 2013). NS5A is, therefore, an attractive antiviral drug target. ABT-333 is an NS5B nucleotide polymerase inhibitor. ABT-333 exhorts its antiviral activity by mimicking the natural substrate of the viral RNA-dependent RNA polymerase

Scope

Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on ABT-450, ABT-333, and ABT-267 including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for ABT-450, ABT-333, and ABT-267 for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of ABT-450, ABT-333, and ABT-267 performance

Obtain sales forecast for ABT-450, ABT-333, and ABT-267 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Table of Contents

1Table of Contents1

1.1List of Tables3

1.2List of Figures3

2Executive Summary4

2.1Sales for AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 in the HCV Market4

2.2What Do the Physicians Think?5

3Introduction6

3.1Catalyst6

3.2Related Reports6

3.3Upcoming Related Reports7

4Disease Overview8

4.1Etiology and Pathophysiology8

4.1.1Etiology8

4.1.2Pathophysiology12

4.1.3Prognosis13

4.2Symptoms13

5Disease Management13

5.1Diagnosis and Referral Overview13

5.2Treatment Overview14

6Competitive Assessment16

6.1Overview16

6.2Strategic Competitor Assessment16

7Opportunity and Unmet Need18

7.1Overview18

7.2Unmet Needs19

7.2.1Unmet Need: Treatment Tolerability19

7.2.2Unmet Need: Efficacy20

7.2.3Unmet Need: Disease Awareness20

7.2.4Unmet Need: Treatment Cost21

7.2.5Unmet Need: Shorter Treatment Duration21

7.2.6Unmet Need: Simplified Treatment Regimens22

7.3Unmet Needs Gap Analysis22

7.4Opportunities23

7.4.1Opportunity: Pan-genotypic HCV Regimen23

7.4.2Opportunity: Treatment of Underrepresented Patient Populations23

7.4.3Opportunity: Involvement of Immune System23

8Pipeline Assessment24

8.1Overview24

8.2Promising Drugs in Clinical Development25

9AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-26726

9.1Overview26

9.2Efficacy28

9.3Safety29

9.4Dosing and Formulation29

9.5Potential Clinical Positioning29

9.6Potential Commercial Positioning29

9.7Pricing and Reimbursement30

9.8SWOT Analysis30

9.9Forecast31

10Appendix32

10.1Bibliography32

10.2Abbreviations36

10.3Methodology36

10.4Forecasting Methodology37

10.4.1Percent Drug-Treated Patients37

10.4.2Patient Warehousing38

10.4.3General Pricing Assumptions38

10.4.4Generic Erosion39

10.4.5Pricing of Pipeline Agents39

10.5Physicians and Specialists Included in this Study39

10.6Survey of Prescribing Physicians41

10.7About the Authors42

10.7.1Author42

10.7.2Global Head of Healthcare42

10.8About GlobalData43

10.9Contact Us43

10.10Disclaimer43

List of Tables

Table 1: AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267: Key Metrics in Nine Major Pharmaceutical Markets4

Table 2: Modes of HCV Transmission12

Table 3: Symptoms of Acute and Chronic HCV Infection13

Table 4: HCV Genotypes Present in the 9MM14

Table 5: General Standard of Care by HCV Genotype14

Table 6: Treatment Guidelines for HCV by Country15

Table 7: Most-Prescribed Drugs for HCV by Class in the Global Markets, 201316

Table 8: Leading Treatments for HCV, 201218

Table 9: Overall Unmet Needs – Current Level of Attainment19

Table 10: Clinical Unmet Needs – Gap Analysis, 201222

Table 11: HCV – Pipeline, 201225

Table 12: Comparison of Therapeutic Classes in Development for HCV, 201226

Table 13: AbbVie’s Combination Therapy Ongoing Clinical Trials of Interest27

Table 14: Product Profile – AbbVie Combination Therapy28

Table 15: AVIATOR Clinical Trial Results28

Table 16: AbbVie Combination Therapy SWOT Analysis, 201231

Table 17: Global Sales Forecasts ($m) for AbbVie Combination Therapy, 2012–202232

Table 18: Physicians Surveyed, By Country41

List of Figures

Figure 1: Sales for AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 by Region, 2012 – 20225

Figure 2: HCV Genome and Polyprotein Composition9

Figure 3: HCV Lifecycle Overview10

Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012–202225

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports